SOPHiA GENETICS Announces Major Expansion in the United States with the Signing of Two Major Integrated Health Systems

Core Insights - SOPHiA GENETICS has announced a significant expansion in the United States by partnering with two major integrated health systems, enhancing its network and capabilities in AI-driven precision medicine [1] Company Expansion - The two new health systems are among the largest in the U.S., collectively analyzing millions of genetic samples annually [1] - The partnership will enable genomic testing for up to 60,000 patients annually across the West Coast and Midwest, focusing on hereditary cancers and rare diseases [1] Technology Utilization - Both health systems will implement SOPHiA DDM™, an AI-driven analytics application that supports comprehensive full-exome analysis for over 20,000 genes [1] - The integration of SOPHiA DDM™ aims to expedite testing turnaround times, reduce operational costs, and foster internal research and innovation initiatives [1] Market Positioning - This collaboration positions SOPHiA GENETICS and its partners to support future expansion in AI-driven precision medicine, serving a combined population of nearly one million cancer and rare disorder patients nationwide [1] - The expansion reinforces the company's mission to democratize data-driven medicine by providing AI-powered solutions that accelerate healthcare innovation and research [1]